Practice-changing DREAMseq melanoma trial, neuroendocrine tumors trial E2211, 8-year survival rates in CHAARTED prostate trial, outcomes by tobacco use in E3311 head and neck study, and analysis showing state-mandated Medicaid coverage of trials boosts Black participation
Philadelphia, May 27, 2022 — Researchers with the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) will present a wide range of study results at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago and online June 3-7. The data include evaluations of new approaches to cancer treatment, control, care delivery, and health equity. The National Cancer Institute, part of the National Institutes of Health, funded these studies.
To request an interview with one of the authors, send an email to Diane Dragaud, Director of Communications, or call 215-789-3631.